Novavax expects U.S. trial data for COVID-19 vaccine at start of April
(Reuters) - Novavax Inc. expects evidence to be sent for an immediate usage authorisation from a late-stage U.S. evaluation of its COVID-19 vaccine at the beginning of April, Drug Developer Head Gregory Glenn said on Wednesday.
"We are expecting results right in the beginning of quarter two and shortly thereafter we will be filing for EUA (in U.S.)," he said at an online event organized by The Washington Post.
The Novavax executive said that in UK trials the vaccine showed a "safety profile" and the firm could ask the US.
The Food and Drug Administration shall accept UK data for authorisation of vaccines.
On Monday, Novavax completed 30,000 late-stage research volunteers in the United States and Mexico.
The firm said its vaccine last month was 89.3 percent successful in stopping COVID-19 in a United Kingdom trial.
It was just as successful against the extremely infectious variant that was first found in the UK.
(Mrinalika Roy's paper in Bengaluru; Arun Koyyur's report)